PP2B, but not PP1/PP2A, is involved in the NMDA-induced dephosphorylation of pS295. by Takahiko Chimura (729098)

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

Particle distribution curve: (a) Fine sand; (b) Coarse sand. by YongHe Liu (20477123)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

This file includes a supplementary figure relevant to the main body of the manuscript. by Aahan Arif (20189512)

Subjects:

Clinic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Demographic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

(A) The distribution of mutations within the 3D structure of the TP53 protein. by Ashraf Attia Mahmoud (21262201)

Subjects:

Estimated marginal mean (± SE) age group differences in the relative frequency of releases per minute, performed by professional soccer players on a match day for each position. by Emily Escreet (20552634)

Subjects: “…tailed statistical significance…”

A) Calcium carbonate crystal size versus ferric ion concentration; B) SEM image at ferric ion concentration of 0.03 M; C) Ferric hydroxide colloid. by Jin Zhu (164147)

Subjects: “…permeability coefficients decreased…”

Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer by Philippine Granger Joly de Boissel (21688159)

Subjects:

Spectral analyses of highly temporally resolved proxy records using the "redfit" (A-C) and multitaper (D-F) methods. by Jose Dominick Guballa (19739909)

Subjects:

Data Sheet 1_Ribosomal protein L9 is a potential therapeutic target for B-ALL through the activation of the p53 signaling pathway.docx by Xinxin Li (281237)

“…In this study, we observed a significant upregulation of RPL9 in human B-ALL cells compared to normal B cells, suggesting RPL9’s potential key role in B-ALL progression. …”

Table 2_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”

Table 1_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”

Table 3_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”